Influenza: Epidemiology, Clinical Features, Therapy, and Prevention

ABSTRACT

Influenza A and B are important causes of respiratory illness in all age groups. Influenza causes seasonal outbreaks globally and, less commonly, pandemics. In the United States, seasonal influenza epidemics account for >200,000 hospitalizations and >30,000 deaths annually. More than 90% of deaths occur in the elderly population. Interestingly, in the novel 2009 H1N1 influenza pandemic, attack rates were highest among children and young adults. Fewer than 10% of cases occurred in adults >60 years old, likely because preexisting antibodies against other H1N1 viruses afforded protection. Despite concerns about a high lethality rate with the novel 2009 H1N1 strain, most illnesses caused by the 2009 H1N1 viruses were mild (overall case fatality rate <0.5%). Clinical features of influenza infection overlap with other respiratory pathogens (particularly viruses). The diagnosis is often delayed due to low suspicion and the limited use of specific diagnostic tests. Rapid diagnostic tests are widely available and allow detection of influenza antigen in respiratory secretions within 1 hour; however, sensitivity ranges from 50 to 90%. Neuraminidase inhibitors (NAIs) (eg, oseltamivir and zanamivir) are effective for treating influenza A or B and for prophylaxis in selected adults and children. Resistance to NAIs is rare, but influenza strains resistant to oseltamivir have been detected. Vaccines are the cornerstone of influenza control. Currently, trivalent inactivated vaccine (TIV) and live attenuated influenza vaccine (LAIV) are available. These agents reduce mortality and morbidity in high-risk patients (i.e., the elderly or patients with comorbidities), and expanding the use of vaccines to healthy children and adults reduces the incidence of influenza, pneumonia, and hospitalizations due to respiratory illnesses in the community.

KEYWORDS

Influenza A and B - epidemics - pandemics - novel H1N1 influenza - neuraminidase inhibitors - vaccination

REFERENCES

• 1 Petric M, Comanor L, Petti C A. Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics.  J Infect Dis. 2006;  194 (Suppl 2) S98-S110
• 2 Lynch III J P, Walsh E E. Influenza: evolving strategies in treatment and prevention.  Semin Respir Crit Care Med. 2007;  28 (2) 144-158
• 3 Gatherer D. The 2009 H1N1 influenza outbreak in its historical context.  J Clin Virol. 2009;  45 (3) 174-178
• 4 Hensley S E, Das S R, Bailey A L et al.. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift.  Science. 2009;  326 (5953) 734-736
• 5 Nichol K L, Treanor J J. Vaccines for seasonal and pandemic influenza.  J Infect Dis. 2006;  194 (Suppl 2) S111-S118
• 6 Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus.  Nature. 2009;  459 (7249) 931-939
• 7 Jayaraman A, Pappas C, Raman R et al.. A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral transmission in ferrets.  PLoS ONE. 2011;  6 (3) e17616
• 8 Kobasa D, Takada A, Shinya K et al.. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus.  Nature. 2004;  431 (7009) 703-707
• 9 Bright R A, Medina M J, Xu X et al.. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.  Lancet. 2005;  366 (9492) 1175-1181
• 10 Brammer L, Blanton L, Epperson S et al.. Surveillance for influenza during the 2009 influenza A (H1N1) pandemic-United States, April 2009-March 2010.  Clin Infect Dis. 2011;  52 (Suppl 1) S27-S35
• 11 Garten R J, Davis C T, Russell C A et al.. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.  Science. 2009;  325 (5937) 197-201
• 12 Fiore A E, Fry A, Shay D, Gubareva L, Bresee J S, Uyeki T M. Centers for Disease Control and Prevention (CDC) . Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2011;  60 (1) 1-24
• 13 Vong S, Coghlan B, Mardy S et al.. Low frequency of poultry-to-human H5NI virus transmission, southern Cambodia, 2005.  Emerg Infect Dis. 2006;  12 (10) 1542-1547
• 14 Abdel-Ghafar A N, Chotpitayasunondh T, Gao Z Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus et al. Update on avian influenza A (H5N1) virus infection in humans.  N Engl J Med. 2008;  358 (3) 261-273
• 15 Rajagopal S, Treanor J. Pandemic (avian) influenza.  Semin Respir Crit Care Med. 2007;  28 (2) 159-170
• 16 Tang J W, Shetty N, Lam T T, Hon K L. Emerging, novel, and known influenza virus infections in humans.  Infect Dis Clin North Am. 2010;  24 (3) 603-617
• 17 Beigel J H, Farrar J, Han A M Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5 et al. Avian influenza A (H5N1) infection in humans.  N Engl J Med. 2005;  353 (13) 1374-1385
• 18 Sedyaningsih E R, Isfandari S, Setiawaty V et al.. Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005–June 2006.  J Infect Dis. 2007;  196 (4) 522-527
• 19 Oner A F, Bay A, Arslan S et al.. Avian influenza A (H5N1) infection in eastern Turkey in 2006.  N Engl J Med. 2006;  355 (21) 2179-2185
• 20 Kandun I N, Wibisono H, Sedyaningsih E R et al.. Three Indonesian clusters of H5N1 virus infection in 2005.  N Engl J Med. 2006;  355 (21) 2186-2194
• 21 Subbarao K, Klimov A, Katz J et al.. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness.  Science. 1998;  279 (5349) 393-396
• 22 Wong S S, Yuen K Y. Avian influenza virus infections in humans.  Chest. 2006;  129 (1) 156-168
• 23 Neuzil K M, Zhu Y, Griffin M R et al.. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study.  J Infect Dis. 2002;  185 (2) 147-152
• 24 Chew F T, Doraisingham S, Ling A E, Kumarasinghe G, Lee B W. Seasonal trends of viral respiratory tract infections in the tropics.  Epidemiol Infect. 1998;  121 (1) 121-128
• 25 Sugaya N, Mitamura K, Yamazaki M et al.. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.  Clin Infect Dis. 2007;  44 (2) 197-202
• 26 Kawai N, Ikematsu H, Iwaki N et al.. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002–2003 influenza season.  Clin Infect Dis. 2005;  40 (9) 1309-1316
• 27 Belser J A, Maines T R, Tumpey T M, Katz J M. Influenza A virus transmission: contributing factors and clinical implications.  Expert Rev Mol Med. 2010;  12 e39
• 28 Lowen A C, Mubareka S, Steel J, Palese P. Influenza virus transmission is dependent on relative humidity and temperature.  PLoS Pathog. 2007;  3 (10) 1470-1476
• 29 Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in human beings.  Lancet Infect Dis. 2007;  7 (4) 257-265
• 30 Glezen W P, Couch R B. Interpandemic influenza in the Houston area, 1974–76.  N Engl J Med. 1978;  298 (11) 587-592
• 31 Fox J P, Cooney M K, Hall C E, Foy H M. Influenzavirus infections in Seattle families, 1975–1979, II: Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness.  Am J Epidemiol. 1982;  116 (2) 228-242
• 32 Monto A S, Kioumehr F. The Tecumseh study of respiratory illness, IX: Occurrence of influenza in the community, 1966–1971.  Am J Epidemiol. 1975;  102 (6) 553-563
• 33 Jain S, Kamimoto L, Bramley A M 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009.  N Engl J Med. 2009;  361 (20) 1935-1944
• 34 Bautista E, Chotpitayasunondh T, Gao Z Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection.  N Engl J Med. 2010;  362 (18) 1708-1719
• 35 Li S, Leader S. Economic burden and absenteeism from influenza-like illness in healthy households with children (5–17 years) in the US.  Respir Med. 2007;  101 (6) 1244-1250
• 36 Thompson W W, Comanor L, Shay D K. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease.  J Infect Dis. 2006;  194 (Suppl 2) S82-S91
• 37 Thompson W W, Shay D K, Weintraub E et al.. Mortality associated with influenza and respiratory syncytial virus in the United States.  JAMA. 2003;  289 (2) 179-186
• 38 Hancock K, Veguilla V, Lu X et al.. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.  N Engl J Med. 2009;  361 (20) 1945-1952
• 39 Osterholm M T. Preparing for the next pandemic.  N Engl J Med. 2005;  352 (18) 1839-1842
• 40 Morens D M, Taubenberger J K, Folkers G K, Fauci A S. Pandemic influenza's 500th anniversary.  Clin Infect Dis. 2010;  51 (12) 1442-1444
• 41 Johnson N P, Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic.  Bull Hist Med. 2002;  76 (1) 105-115
• 42 Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S INER Working Group on Influenza et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico.  N Engl J Med. 2009;  361 (7) 680-689
• 43 Domínguez-Cherit G, Lapinsky S E, Macias A E et al.. Critically Ill patients with 2009 influenza A(H1N1) in Mexico.  JAMA. 2009;  302 (17) 1880-1887
• 44 Fajardo-Dolci G, Gutierrez-Vega R, Arboleya-Casanova H et al.. Clinical characteristics of fatalities due to influenza A (H1N1) virus in Mexico.  Thorax. 2010;  65 (6) 505-509
• 45 Dawood F S, Jain S, Finelli L Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans.  N Engl J Med. 2009;  360 (25) 2605-2615
• 46 Kumar A, Zarychanski R, Pinto R Canadian Critical Care Trials Group H1N1 Collaborative et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada.  JAMA. 2009;  302 (17) 1872-1879
• 47 Webb S A, Pettilä V, Seppelt I ANZIC Influenza Investigators et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand.  N Engl J Med. 2009;  361 (20) 1925-1934
• 48 Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.  Lancet. 2010;  375 (9720) 1100-1108
• 49 Libster R, Bugna J, Coviello S et al.. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina.  N Engl J Med. 2010;  362 (1) 45-55
• 50 Louie J K, Acosta M, Jamieson D J, Honein M A. California Pandemic (H1N1) Working Group . Severe 2009 H1N1 influenza in pregnant and postpartum women in California.  N Engl J Med. 2010;  362 (1) 27-35
• 51 Iuliano A D, Reed C, Guh A et al.. Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April–May 2009.  Clin Infect Dis. 2009;  49 (12) 1811-1820
• 52 Treanor J J. Influenza viruses, including avian influenza and swine influenza. In: Mandell G L, Bennett J E, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia, PA: Churchill Livingstone; 2010: 2265-2288
• 53 Poehling K A, Edwards K M, Weinberg G A New Vaccine Surveillance Network et al. The underrecognized burden of influenza in young children.  N Engl J Med. 2006;  355 (1) 31-40
• 54 Whitley R J, Monto A S. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents.  J Infect Dis. 2006;  194 (Suppl 2) S133-S138
• 55 Whimbey E, Elting L S, Couch R B et al.. Influenza A virus infections among hospitalized adult bone marrow transplant recipients.  Bone Marrow Transplant. 1994;  13 (4) 437-440
• 56 Nichols W G, Guthrie K A, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.  Clin Infect Dis. 2004;  39 (9) 1300-1306
• 57 Kim Y-J, Boeckh M, Englund J A. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection.  Semin Respir Crit Care Med. 2007;  28 (2) 222-242
• 58 Ison M G, Gubareva L V, Atmar R L, Treanor J, Hayden F G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.  J Infect Dis. 2006;  193 (6) 760-764
• 59 Tang J W, Tambyah P A, Lai F Y et al.. Differing symptom patterns in early pandemic vs seasonal influenza infections.  Arch Intern Med. 2010;  170 (10) 861-867
• 60 Shiley K T, Nadolski G, Mickus T, Fishman N O, Lautenbach E. Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza.  Infect Control Hosp Epidemiol. 2010;  31 (7) 676-682
• 61 Centers for Disease Control and Prevention (CDC) . Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives—12 states, 2009.  MMWR Morb Mortal Wkly Rep. 2009;  58 (48) 1341-1344
• 62 Ong A K, Chen M I, Lin L et al.. Improving the clinical diagnosis of influenza—a comparative analysis of new influenza A (H1N1) cases.  PLoS ONE. 2009;  4 (12) e8453
• 63 O'Brien K L, Walters M I, Sellman J et al.. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection.  Clin Infect Dis. 2000;  30 (5) 784-789
• 64 Murata Y, Walsh E E, Falsey A R. Pulmonary complications of interpandemic influenza A in hospitalized adults.  J Infect Dis. 2007;  195 (7) 1029-1037
• 65 Louria D B, Blumenfeld H L, Ellis J T, Kilbourne E D, Rogers D E. Studies on influenza in the pandemic of 1957–1958, II: Pulmonary complications of influenza.  J Clin Invest. 1959;  38 (1 Part 2) 213-265
• 66 Fainstein V, Musher D M, Cate T R. Bacterial adherence to pharyngeal cells during viral infection.  J Infect Dis. 1980;  141 (2) 172-176
• 67 Edelen J S, Bender T R, Chin T D. Encephalopathy and pericarditis during an outbreak of influenza.  Am J Epidemiol. 1974;  100 (2) 79-84
• 68 Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children.  Clin Infect Dis. 2003;  36 (3) 299-305
• 69 Morishima T, Togashi T, Yokota S Collaborative Study Group on Influenza-Associated Encephalopathy in Japan et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan.  Clin Infect Dis. 2002;  35 (5) 512-517
• 70 Belay E D, Bresee J S, Holman R C, Khan A S, Shahriari A, Schonberger L B. Reye's syndrome in the United States from 1981 through 1997.  N Engl J Med. 1999;  340 (18) 1377-1382
• 71 Starko K M, Ray C G, Dominguez L B, Stromberg W L, Woodall D F. Reye's syndrome and salicylate use.  Pediatrics. 1980;  66 (6) 859-864
• 72 Englund J A, Champlin R E, Wyde P R et al.. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults.  Clin Infect Dis. 1998;  26 (6) 1418-1424
• 73 Hirschhorn L R, McIntosh K, Anderson K G, Dermody T S. Influenzal pneumonia as a complication of autologous bone marrow transplantation.  Clin Infect Dis. 1992;  14 (3) 786-787
• 74 Ljungman P, Andersson J, Aschan J et al.. Influenza A in immunocompromised patients.  Clin Infect Dis. 1993;  17 (2) 244-247
• 75 Apalsch A M, Green M, Ledesma-Medina J, Nour B, Wald E R. Parainfluenza and influenza virus infections in pediatric organ transplant recipients.  Clin Infect Dis. 1995;  20 (2) 394-399
• 76 Neuzil K M, Reed G W, Mitchel E F, Simonsen L, Griffin M R. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women.  Am J Epidemiol. 1998;  148 (11) 1094-1102
• 77 O'Brien M A, Uyeki T M, Shay D K et al.. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children.  Pediatrics. 2004;  113 (3 Pt 1) 585-593
• 78 Grijalva C G, Craig A S, Dupont W D et al.. Estimating influenza hospitalizations among children.  Emerg Infect Dis. 2006;  12 (1) 103-109
• 79 Izurieta H S, Thompson W W, Kramarz P et al.. Influenza and the rates of hospitalization for respiratory disease among infants and young children.  N Engl J Med. 2000;  342 (4) 232-239
• 80 Meltzer M I, Neuzil K M, Griffin M R, Fukuda K. An economic analysis of annual influenza vaccination of children.  Vaccine. 2005;  23 (8) 1004-1014
• 81 Neuzil K M, Mellen B G, Wright P F, Mitchel Jr E F, Griffin M R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.  N Engl J Med. 2000;  342 (4) 225-231
• 82 Bhat N, Wright J G, Broder K R Influenza Special Investigations Team et al. Influenza-associated deaths among children in the United States, 2003–2004.  N Engl J Med. 2005;  353 (24) 2559-2567
• 83 Bonner A B, Monroe K W, Talley L I, Klasner A E, Kimberlin D W. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial.  Pediatrics. 2003;  112 (2) 363-367
• 84 Call S A, Vollenweider M A, Hornung C A, Simel D L, McKinney W P. Does this patient have influenza?.  JAMA. 2005;  293 (8) 987-997
• 85 Walsh E E, Cox C, Falsey A R. Clinical features of influenza A virus infection in older hospitalized persons.  J Am Geriatr Soc. 2002;  50 (9) 1498-1503
• 86 Monto A S, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection.  Arch Intern Med. 2000;  160 (21) 3243-3247
• 87 Peltola V, Reunanen T, Ziegler T, Silvennoinen H, Heikkinen T. Accuracy of clinical diagnosis of influenza in outpatient children.  Clin Infect Dis. 2005;  41 (8) 1198-1200
• 88 Harper S A, Bradley J S, Englund J A Expert Panel of the Infectious Diseases Society of America et al. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.  Clin Infect Dis. 2009;  48 (8) 1003-1032
• 89 Centers for Disease Control and Prevention .Guidance for clinicians on the use of rapid influenza diagnostic tests for the 2010–2011 influenza season. December 22, 2010. http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm Accessed March 25, 2011
• 90 McGeer A J. Diagnostic testing or empirical therapy for patients hospitalized with suspected influenza: what to do?.  Clin Infect Dis. 2009;  48 (Suppl 1) S14-S19
• 91 Uyeki T M. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza.  Pediatr Infect Dis J. 2003;  22 (2) 164-177
• 92 Weinberg G A, Erdman D D, Edwards K M New Vaccine Surveillance Network Study Group et al. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children.  J Infect Dis. 2004;  189 (4) 706-710
• 93 Sharma V, Dowd M D, Slaughter A J, Simon S D. Effect of rapid diagnosis of influenza virus type a on the emergency department management of febrile infants and toddlers.  Arch Pediatr Adolesc Med. 2002;  156 (1) 41-43
• 94 Poehling K A, Griffin M R, Dittus R S et al.. Bedside diagnosis of influenzavirus infections in hospitalized children.  Pediatrics. 2002;  110 (1 Pt 1) 83-88
• 95 Couch R B. Prevention and treatment of influenza.  N Engl J Med. 2000;  343 (24) 1778-1787
• 96 Moscona A. Neuraminidase inhibitors for influenza.  N Engl J Med. 2005;  353 (13) 1363-1373
• 97 Hayden F G, Osterhaus A D, Treanor J J et al.. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.  N Engl J Med. 1997;  337 (13) 874-880
• 98 Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.  Arch Intern Med. 2003;  163 (14) 1667-1672
• 99 Monto A S, Fleming D M, Henry D et al.. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.  J Infect Dis. 1999;  180 (2) 254-261
• 100 Nicholson K G, Aoki F Y, Osterhaus A D Neuraminidase Inhibitor Flu Treatment Investigator Group et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial.  Lancet. 2000;  355 (9218) 1845-1850
• 101 Treanor J J, Hayden F G, Vrooman P S US Oral Neuraminidase Study Group et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial.  JAMA. 2000;  283 (8) 1016-1024
• 102 Whitley R J, Hayden F G, Reisinger K S et al.. Oral oseltamivir treatment of influenza in children.  Pediatr Infect Dis J. 2001;  20 (2) 127-133
• 103 Lee N, Cockram C S, Chan P K, Hui D S, Choi K W, Sung J J. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes.  Clin Infect Dis. 2008;  46 (8) 1323-1324
• 104 Louie J K, Acosta M, Winter K California Pandemic (H1N1) Working Group et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California.  JAMA. 2009;  302 (17) 1896-1902
• 105 McGeer A, Green K A, Plevneshi A Toronto Invasive Bacterial Diseases Network et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada.  Clin Infect Dis. 2007;  45 (12) 1568-1575
• 106 Lee N, Choi K W, Chan P K et al.. Outcomes of adults hospitalised with severe influenza.  Thorax. 2010;  65 (6) 510-515
• 107 Wang C, Takeuchi K, Pinto L H, Lamb R A. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block.  J Virol. 1993;  67 (9) 5585-5594
• 108 Monto A S, Ohmit S E, Hornbuckle K, Pearce C L. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes.  Antimicrob Agents Chemother. 1995;  39 (10) 2224-2228
• 109 Younkin S W, Betts R F, Roth F K, Douglas Jr R G. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine.  Antimicrob Agents Chemother. 1983;  23 (4) 577-582
• 110 Dolin R, Reichman R C, Madore H P, Maynard R, Linton P N, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection.  N Engl J Med. 1982;  307 (10) 580-584
• 111 Brady M T, Sears S D, Pacini D L et al.. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic.  Antimicrob Agents Chemother. 1990;  34 (9) 1633-1636
• 112 Reuman P D, Bernstein D I, Keefer M C, Young E C, Sherwood J R, Schiff G M. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A.  Antiviral Res. 1989;  11 (1) 27-40
• 113 Monto A S, Gunn R A, Bandyk M G, King C L. Prevention of Russian influenza by amantadine.  JAMA. 1979;  241 (10) 1003-1007
• 114 Patriarca P A, Kater N A, Kendal A P, Bregman D J, Smith J D, Sikes R K. Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A virus infections in nursing homes.  Antimicrob Agents Chemother. 1984;  26 (1) 101-103
• 115 Galbraith A W, Oxford J S, Schild G C, Watson G I. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study.  Lancet. 1969;  2 (7629) 1026-1028
• 116 Hayden F G, Belshe R B, Clover R D, Hay A J, Oakes M G, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.  N Engl J Med. 1989;  321 (25) 1696-1702
• 117 Keyser L A, Karl M, Nafziger A N, Bertino Jr J S. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.  Arch Intern Med. 2000;  160 (10) 1485-1488
• 118 Weinstock D M, Zuccotti G. Adamantane resistance in influenza A.  JAMA. 2006;  295 (8) 934-936
• 119 Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use.  Arch Intern Med. 1995;  155 (5) 533-537
• 120 Bright R A, Shay D K, Shu B, Cox N J, Klimov A I. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States.  JAMA. 2006;  295 (8) 891-894
• 121 Centers for Disease Control and Prevention (CDC) . Update: influenza activity - United States, 2009–10 season.  MMWR Morb Mortal Wkly Rep. 2010;  59 (29) 901-908
• 122 Centers for Disease Control and Prevention (CDC) . High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents—United States, 2005–06 influenza season.  MMWR Morb Mortal Wkly Rep. 2006;  55 (2) 44-46
• 123 Smith N M, Bresee J S, Shay D K, Uyeki T M, Cox N J, Strikas R A. Advisory Committee on Immunization Practices . Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2006;  55 (RR-10) 1-42
• 124 Oxford J, Balasingam S, Lambkin R. A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.  J Antimicrob Chemother. 2004;  53 (2) 133-136
• 125 Cooper N J, Sutton A J, Abrams K R, Wailoo A, Turner D, Nicholson K G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.  BMJ. 2003;  326 (7401) 1235
• 126 Moscona A. Oseltamivir resistance—disabling our influenza defenses.  N Engl J Med. 2005;  353 (25) 2633-2636
• 127 Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.  Antiviral Res. 2002;  54 (3) 143-147
• 128 Gaur A H, Bagga B, Barman S et al.. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza.  N Engl J Med. 2010;  362 (1) 88-89
• 129 Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: a review of clinical safety.  Drug Saf. 1999;  21 (4) 267-281
• 130 Centers for Disease Control and Prevention (CDC) . Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—North Carolina, 2009.  MMWR Morb Mortal Wkly Rep. 2009;  58 (35) 969-972
• 131 Le Q M, Wertheim H F, Tran N D, van Doorn H R, Nguyen T H, Horby P. Vietnam H1N1 Investigation Team . A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza.  N Engl J Med. 2010;  362 (1) 86-87
• 132 Stephenson I, Democratis J, Lackenby A et al.. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.  Clin Infect Dis. 2009;  48 (4) 389-396
• 133 Genentech, USAI .Tamiflu Prescribing Information. San Francisco, CA: Genentech, USA, Inc.; 2011
• 134 Kimberlin D W, Shalabi M, Abzug M J NIAID Collaborative Antiviral Study Group et al. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age.  Pediatr Infect Dis J. 2010;  29 (3) 195-198
• 135 Hayden F G, Belshe R, Villanueva C et al.. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.  J Infect Dis. 2004;  189 (3) 440-449
• 136 McClellan K, Perry C M. Oseltamivir: a review of its use in influenza.  Drugs. 2001;  61 (2) 263-283
• 137 GlaxoSmithKline .Relenza Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; 2010
• 138 The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group . Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections.  Lancet. 1998;  352 (9144) 1877-1881
• 139 Monto A S, Pichichero M E, Blanckenberg S J et al.. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households.  J Infect Dis. 2002;  186 (11) 1582-1588
• 140 Cass L M, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.  Clin Pharmacokinet. 1999;  36 (Suppl 1) 1-11
• 141 Steel H M, Peppercorn A F. Fatal respiratory events caused by zanamivir nebulization.  Clin Infect Dis. 2010;  51 (1) 121
• 142 Härter G, Zimmermann O, Maier L et al.. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus.  Clin Infect Dis. 2010;  50 (9) 1249-1251
• 143 Hernandez J E, Adiga R, Armstrong R eIND Peramivir Investigators et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States.  Clin Infect Dis. 2011;  52 (6) 695-706
• 144 Mäkelä M J, Pauksens K, Rostila T et al.. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.  J Infect. 2000;  40 (1) 42-48
• 145 Matsumoto K, Ogawa N, Nerome K et al.. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.  Antivir Ther. 1999;  4 (2) 61-68
• 146 Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials.  Arch Intern Med. 2001;  161 (2) 212-217
• 147 Hedrick J A, Barzilai A, Behre U et al.. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.  Pediatr Infect Dis J. 2000;  19 (5) 410-417
• 148 Aoki F Y, Macleod M D, Paggiaro P IMPACT Study Group et al. Early administration of oral oseltamivir increases the benefits of influenza treatment.  J Antimicrob Chemother. 2003;  51 (1) 123-129
• 149 Heinonen S, Silvennoinen H, Lehtinen P et al.. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial.  Clin Infect Dis. 2010;  51 (8) 887-894
• 150 Falagas M E, Koletsi P K, Vouloumanou E K, Rafailidis P I, Kapaskelis A M, Rello J. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials.  J Antimicrob Chemother. 2010;  65 (7) 1330-1346
• 151 Bowles S K, Lee W, Simor A E Oseltamivir Compassionate Use Program Group et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.  J Am Geriatr Soc. 2002;  50 (4) 608-616
• 152 Kaiser L, Keene O N, Hammond J M, Elliott M, Hayden F G. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults.  Arch Intern Med. 2000;  160 (21) 3234-3240
• 153 Nordstrom B L, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir.  Curr Med Res Opin. 2005;  21 (5) 761-768
• 154 Hanshaoworakul W, Simmerman J M, Narueponjirakul U et al.. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome.  PLoS ONE. 2009;  4 (6) e6051
• 155 Hiba V, Chowers M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study.  J Antimicrob Chemother. 2011;  66 (5) 1150-1155
• 156 Hayden F G, Atmar R L, Schilling M et al.. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.  N Engl J Med. 1999;  341 (18) 1336-1343
• 157 Welliver R, Monto A S, Carewicz O Oseltamivir Post Exposure Prophylaxis Investigator Group et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.  JAMA. 2001;  285 (6) 748-754
• 158 Monto A S, Rotthoff J, Teich E et al.. Detection and control of influenza outbreaks in well-vaccinated nursing home populations.  Clin Infect Dis. 2004;  39 (4) 459-464
• 159 Peters Jr P H, Gravenstein S, Norwood P et al.. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population.  J Am Geriatr Soc. 2001;  49 (8) 1025-1031
• 160 Rothberg M B, Bellantonio S, Rose D N. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.  Ann Intern Med. 2003;  139 (5 Pt 1) 321-329
• 161 Monto A S, Robinson D P, Herlocher M L, Hinson Jr J M, Elliott M J, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial.  JAMA. 1999;  282 (1) 31-35
• 162 Hayden F G, Gubareva L V, Monto A S Zanamivir Family Study Group et al. Inhaled zanamivir for the prevention of influenza in families.  N Engl J Med. 2000;  343 (18) 1282-1289
• 163 Cass L M, Gunawardena K A, Macmahon M M, Bye A. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir.  Respir Med. 2000;  94 (2) 166-173
• 164 Toovey S, Rayner C, Prinssen E et al.. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.  Drug Saf. 2008;  31 (12) 1097-1114
• 165 Yen H L, Herlocher L M, Hoffmann E et al.. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.  Antimicrob Agents Chemother. 2005;  49 (10) 4075-4084
• 166 Gubareva L V, Kaiser L, Hayden F G. Influenza virus neuraminidase inhibitors.  Lancet. 2000;  355 (9206) 827-835
• 167 McKimm-Breschkin J, Trivedi T, Hampson A et al.. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.  Antimicrob Agents Chemother. 2003;  47 (7) 2264-2272
• 168 Moscona A. Oseltamivir-resistant influenza?.  Lancet. 2004;  364 (9436) 733-734
• 169 Brett A S, Zuger A. The run on Tamiflu—should physicians prescribe on demand?.  N Engl J Med. 2005;  353 (25) 2636-2637
• 170 Tamura D, Sugaya N, Ozawa M et al.. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.  Clin Infect Dis. 2011;  52 (4) 432-437
• 171 Gubareva L V, Matrosovich M N, Brenner M K, Bethell R C, Webster R G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.  J Infect Dis. 1998;  178 (5) 1257-1262
• 172 Hauge S H, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08.  Emerg Infect Dis. 2009;  15 (2) 155-162
• 173 Dharan N J, Gubareva L V, Meyer J J Oseltamivir-Resistance Working Group et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.  JAMA. 2009;  301 (10) 1034-1041
• 174 Ujike M, Shimabukuro K, Mochizuki K Working Group for Influenza Virus Surveillance in Japan et al. Oseltamivir-resistant influenza viruses A (H1N1) during 2007–2009 influenza seasons, Japan.  Emerg Infect Dis. 2010;  16 (6) 926-935
• 175 Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin M E, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.  N Engl J Med. 2009;  361 (23) 2296-2297
• 176 Schwartz B, Hinman A, Abramson J et al.. Universal influenza vaccination in the United States: are we ready? Report of a meeting.  J Infect Dis. 2006;  194 (Suppl 2) S147-S154
• 177 Schmidt A C. Progress in respiratory virus vaccine development.  Semin Respir Crit Care Med. 2007;  28 (2) 243-252
• 178 Fiore A E, Uyeki T M, Broder K Centers for Disease Control and Prevention (CDC) et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.  MMWR Recomm Rep. 2010;  59 (RR-8) 1-62
• 179 Fukuda K, Kieny M P. Different approaches to influenza vaccination.  N Engl J Med. 2006;  355 (24) 2586-2587
• 180 World Health Organization . Recommended viruses for influenza vaccines for use in the 2010–2011 northern hemisphere influenza season.  Wkly Epidemiol Rec. 2010;  85 (10) 81-92
• 181 Bridges C B, Thompson W W, Meltzer M I et al.. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial.  JAMA. 2000;  284 (13) 1655-1663
• 182 Schultz-Cherry S, Jones J C. Influenza vaccines: the good, the bad, and the eggs.  Adv Virus Res. 2010;  77 63-84
• 183 National Center for Immunization and Respiratory Diseases, CDC . Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.  MMWR Recomm Rep. 2009;  58 (RR-10) 1-8
• 184 Ohmit S E, Victor J C, Rotthoff J R et al.. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines.  N Engl J Med. 2006;  355 (24) 2513-2522
• 185 Belshe R B, Mendelman P M, Treanor J et al.. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.  N Engl J Med. 1998;  338 (20) 1405-1412
• 186 Harper S A, Fukuda K, Uyeki T M, Cox N J, Bridges C B. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC) . Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2005;  54 (RR-8) 1-40
• 187 Englund J A, Walter E, Black S GRC28 Study Team et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.  Pediatr Infect Dis J. 2010;  29 (2) 105-110
• 188 Centers for Disease Control and Prevention (CDC) . Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use—United States, 2010.  MMWR Morb Mortal Wkly Rep. 2010;  59 (16) 485-486
• 189 Falsey A R, Treanor J J, Tornieporth N, Capellan J, Gorse G J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.  J Infect Dis. 2009;  200 (2) 172-180
• 190 Small Jr P A, Bender B S. Vaccination against influenza in healthy adults.  N Engl J Med. 1996;  334 (6) 402-403 author reply 403-404
• 191 Nichol K L, Lind A, Margolis K L et al.. The effectiveness of vaccination against influenza in healthy, working adults.  N Engl J Med. 1995;  333 (14) 889-893
• 192 Nichol K L. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.  Arch Intern Med. 2001;  161 (5) 749-759
• 193 Demicheli V, Rivetti D, Deeks J J, Jefferson T O. Vaccines for preventing influenza in healthy adults.  Cochrane Database Syst Rev. 2004;  (3) CD001269
• 194 Gross P A, Hermogenes A W, Sacks H S, Lau J, Levandowski R A. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature.  Ann Intern Med. 1995;  123 (7) 518-527
• 195 Ohmit S E, Arden N H, Monto A S. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic.  J Am Geriatr Soc. 1999;  47 (2) 165-171
• 196 Monto A S, Ohmit S E, Petrie J G et al.. Comparative efficacy of inactivated and live attenuated influenza vaccines.  N Engl J Med. 2009;  361 (13) 1260-1267
• 197 Belshe R B, Edwards K M, Vesikari T CAIV-T Comparative Efficacy Study Group et al. Live attenuated versus inactivated influenza vaccine in infants and young children.  N Engl J Med. 2007;  356 (7) 685-696
• 198 Wang Z, Tobler S, Roayaei J, Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel.  JAMA. 2009;  301 (9) 945-953
• 199 Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché M K, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.  Lancet. 2010;  375 (9708) 41-48
• 200 Potter J, Stott D J, Roberts M A et al.. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients.  J Infect Dis. 1997;  175 (1) 1-6
• 201 Wilde J A, McMillan J A, Serwint J, Butta J, O'Riordan M A, Steinhoff M C. Effectiveness of influenza vaccine in health care professionals: a randomized trial.  JAMA. 1999;  281 (10) 908-913
• 202 Pearson M L, Bridges C B, Harper S A. Healthcare Infection Control Practices Advisory Committee (HICPAC) . Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2006;  55 (RR-2) 1-16
• 203 Carman W F, Elder A G, Wallace L A et al.. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial.  Lancet. 2000;  355 (9198) 93-97
• 204 Burls A, Jordan R, Barton P et al.. Vaccinating healthcare workers against influenza to protect the vulnerable—is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation.  Vaccine. 2006;  24 (19) 4212-4221
• 205 Lemaitre M, Meret T, Rothan-Tondeur M et al.. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial.  J Am Geriatr Soc. 2009;  57 (9) 1580-1586
• 206 Centers for Disease Control and Prevention .Prevention strategies for seasonal influenza in healthcare settings. September 20, 2010. http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm Accessed April 2, 2011
• 207 Talbot T R, Babcock H, Caplan A L et al.. Revised SHEA position paper: influenza vaccination of healthcare personnel.  Infect Control Hosp Epidemiol. 2010;  31 (10) 987-995
• 208 Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.  Vaccine. 2002;  20 (13–14) 1831-1836
• 209 Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review.  Lancet. 2005;  366 (9492) 1165-1174
• 210 Nichol K L, Margolis K L, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.  N Engl J Med. 1994;  331 (12) 778-784
• 211 Fedson D S, Wajda A, Nicol J P, Hammond G W, Kaiser D L, Roos L L. Clinical effectiveness of influenza vaccination in Manitoba.  JAMA. 1993;  270 (16) 1956-1961
• 212 Foster D A, Talsma A, Furumoto-Dawson A et al.. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly.  Am J Epidemiol. 1992;  136 (3) 296-307
• 213 Arden N, Monto A S, Ohmit S E. Vaccine use and the risk of outbreaks in a sample of nursing homes during an influenza epidemic.  Am J Public Health. 1995;  85 (3) 399-401
• 214 Monto A S, Hornbuckle K, Ohmit S E. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study.  Am J Epidemiol. 2001;  154 (2) 155-160
• 215 Mullooly J P, Bennett M D, Hornbrook M C et al.. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization.  Ann Intern Med. 1994;  121 (12) 947-952
• 216 Nichol K L, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens.  Arch Intern Med. 1998;  158 (16) 1769-1776
• 217 Nichol K L, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly.  N Engl J Med. 2003;  348 (14) 1322-1332
• 218 Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers.  Int J STD AIDS. 1997;  8 (12) 776-779
• 219 Blumberg E A, Albano C, Pruett T et al.. The immunogenicity of influenza virus vaccine in solid organ transplant recipients.  Clin Infect Dis. 1996;  22 (2) 295-302
• 220 Hak E, Buskens E, van Essen G A et al.. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study.  Arch Intern Med. 2005;  165 (3) 274-280
• 221 Looijmans-Van den Akker I, Verheij T J, Buskens E, Nichol K L, Rutten G E, Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients.  Diabetes Care. 2006;  29 (8) 1771-1776
• 222 Fine A D, Bridges C B, De Guzman A M et al.. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City.  Clin Infect Dis. 2001;  32 (12) 1784-1791
• 223 Nichol K L, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.  Ann Intern Med. 1999;  130 (5) 397-403
• 224 Podewils L J, Liedtke L A, McDonald L C Infectious Diseases Society of America Emerging Infections Network et al. A national survey of severe influenza-associated complications among children and adults, 2003-2004.  Clin Infect Dis. 2005;  40 (11) 1693-1696
• 225 Hurwitz E S, Haber M, Chang A et al.. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts.  JAMA. 2000;  284 (13) 1677-1682
• 226 Reichert T A, Sugaya N, Fedson D S, Glezen W P, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza.  N Engl J Med. 2001;  344 (12) 889-896
• 227 Piedra P A, Gaglani M J, Kozinetz C A et al.. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children.  Vaccine. 2005;  23 (13) 1540-1548
• 228 Monto A S, Davenport F M, Napier J A, Francis Jr T. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren.  J Infect Dis. 1970;  122 (1) 16-25
• 229 Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review.  Lancet. 2005;  365 (9461) 773-780
• 230 Negri E, Colombo C, Giordano L, Groth N, Apolone G, La Vecchia C. Influenza vaccine in healthy children: a meta-analysis.  Vaccine. 2005;  23 (22) 2851-2861
• 231 Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children.  Am J Dis Child. 1991;  145 (4) 445-448
• 232 Weller S C, Mann N C. Influenza vaccination and acute otitis media in children.  Am J Dis Child. 1992;  146 (9) 1018-1019
• 233 Clements D A, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care.  Arch Pediatr Adolesc Med. 1995;  149 (10) 1113-1117
• 234 Brownstein J S, Kleinman K P, Mandl K D. Identifying pediatric age groups for influenza vaccination using a real-time regional surveillance system.  Am J Epidemiol. 2005;  162 (7) 686-693
• 235 Jordan R, Connock M, Albon E et al.. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence.  Vaccine. 2006;  24 (8) 1047-1062
• 236 Centers for Disease Control and Prevention . Prevention and control of influenza: recommendations of the Immunization Practices Advisory Committee (ACIP).  MMWR Recomm Rep. 1990;  39 (RR-7) 1-15
• 237 Centers for Disease Control and Prevention . Influenza vaccination levels in selected states–Behavioral Risk Factor Surveillance System, 1987.  MMWR Morb Mortal Wkly Rep. 1989;  38 (8) 124 129-133
• 238 Centers for Disease Control and Prevention . Prevention and control of influenza, I: Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 1994;  43 (RR-9) 1-13
• 239 Bridges C B, Winquist A G, Fukuda K, Cox N J, Singleton J A, Strikas R A. Advisory Committee on Immunization Practices . Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2000;  49 (RR-3) 1-38 quiz CE1-CE7
• 240 Bridges C B, Fukuda K, Uyeki T M, Cox N J, Singleton J A. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices . Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2002;  51 (RR-3) 1-31
• 241 Hemingway C O, Poehling K A. Change in recommendation affects influenza vaccinations among children 6 to 59 months of age.  Pediatrics. 2004;  114 (4) 948-952
• 242 Arden N H. Control of influenza in the long-term-care facility: a review of established approaches and newer options.  Infect Control Hosp Epidemiol. 2000;  21 (1) 59-64
• 243 Centers for Disease Control and Prevention (CDC) . Influenza vaccination coverage among children and adults—United States, 2008–09 influenza season.  MMWR Morb Mortal Wkly Rep. 2009;  58 (39) 1091-1095
• 244 Lee T H. Rationing influenza vaccine.  N Engl J Med. 2004;  351 (23) 2365-2366
• 245 Nichol K L, Margolis K L, Lind A et al.. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial.  Arch Intern Med. 1996;  156 (14) 1546-1550
• 246 Margolis K L, Nichol K L, Poland G A, Pluhar R E. Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial.  JAMA. 1990;  264 (9) 1139-1141
• 247 Greene S K, Kulldorff M, Lewis E M et al.. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.  Am J Epidemiol. 2010;  171 (2) 177-188
• 248 Mak T K, Mangtani P, Leese J, Watson J M, Pfeifer D. Influenza vaccination in pregnancy: current evidence and selected national policies.  Lancet Infect Dis. 2008;  8 (1) 44-52
• 249 James J M, Zeiger R S, Lester M R et al.. Safe administration of influenza vaccine to patients with egg allergy.  J Pediatr. 1998;  133 (5) 624-628
• 250 Hurwitz E S, Schonberger L B, Nelson D B, Holman R C. Guillain-Barré syndrome and the 1978–1979 influenza vaccine.  N Engl J Med. 1981;  304 (26) 1557-1561
• 251 Schonberger L B, Bregman D J, Sullivan-Bolyai J Z et al.. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977.  Am J Epidemiol. 1979;  110 (2) 105-123
• 252 Marks J S, Halpin T J. Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine.  JAMA. 1980;  243 (24) 2490-2494
• 253 Lasky T, Terracciano G J, Magder L et al.. The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines.  N Engl J Med. 1998;  339 (25) 1797-1802
• 254 Centers for Disease Control and Prevention . Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 1998;  47 (RR-6) 1-26
• 255 Sivadon-Tardy V, Orlikowski D, Porcher R et al.. Guillain-Barré syndrome and influenza virus infection.  Clin Infect Dis. 2009;  48 (1) 48-56
• 256 King Jr J C, Stoddard J J, Gaglani M J et al.. Effectiveness of school-based influenza vaccination.  N Engl J Med. 2006;  355 (24) 2523-2532
• 257 Nichol K L, Mendelman P M, Mallon K P et al.. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.  JAMA. 1999;  282 (2) 137-144
• 258 Jackson L A, Holmes S J, Mendelman P M, Huggins L, Cho I, Rhorer J. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions.  Vaccine. 1999;  17 (15–16) 1905-1909
• 259 King Jr J C, Fast P E, Zangwill K M HIV Influenza Study Group et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.  Pediatr Infect Dis J. 2001;  20 (12) 1124-1131
• 260 Grayson M L, Melvani S, Druce J et al.. Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers.  Clin Infect Dis. 2009;  48 (3) 285-291
• 261 Aiello A E, Murray G F, Perez V et al.. Mask use, hand hygiene, and seasonal influenza-like illness among young adults: a randomized intervention trial.  J Infect Dis. 2010;  201 (4) 491-498
• 262 Cowling B J, Chan K H, Fang V J et al.. Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial.  Ann Intern Med. 2009;  151 (7) 437-446